Insight in modulation of inflammation in response to diclofenac intervention: A human intervention study

BMC Medical Genomics

Volumn 3, Issue , 2010, Pages

  Van Erk, Marjan J ^a   Wopereis, Suzan ^a   Rubingh, Carina ^a   Van Vliet, Trinette ^a,b   Verheij, Elwin ^a   Cnubben, Nicole Hp ^a   Pedersen, Theresa L ^c   Newman, John W ^c,d   Smilde, Age K ^a,e   Greef, Jan Van Der ^a   Hendriks, Henk Fj ^a   Van Ommen, Ben ^a  

^a TNO   (Netherlands)

^b CCMO   (Netherlands)

^c AGRICULTURAL RESEARCH SERVICE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; CASPASE 8; DICLOFENAC; FATTY ACID; GENE PRODUCT; LIPID; LIPOCORTIN 1; PLACEBO; PLASMA PROTEIN; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FATTY ACID BLOOD LEVEL; GENE EXPRESSION; HUMAN; INFLAMMATION; INTERVENTION STUDY; LIPID BLOOD LEVEL; MALE; OBESITY; OSTEOARTHRITIS; PARALLEL DESIGN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; BLOOD; BODY MASS; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; METABOLOMICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROTEOMICS;

ADULT; ANNEXIN A1; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BODY MASS INDEX; CASPASE 8; DICLOFENAC; DINOPROSTONE; GENE EXPRESSION PROFILING; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; METABOLOMICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; OVERWEIGHT; PROTEOMICS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77649324786     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-3-5     Document Type: Article

References (35)

1. Adipose tissue, inflammation, and cardiovascular disease. AH Berg PE Scherer, Circulation Research 2005 96 939 949 10.1161/01.RES.0000163635.62927.34 15890981
2. Physiological role of adipose tissue: White adipose tissue as an endocrine and secretory organ. P Trayhurn JH Beattie, Proceedings of the Nutrition Society 2001 60 329 339 10.1079/PNS200194 11681807
3. C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study. AR Folsom N Aleksic D Catellier HS Juneja KK Wu, American Heart Journal 2002 144 233 238 10.1067/mhj.2002.124054 12177639
4. Markers of inflammation and coronary artery disease. SM Saadeddin MA Habbab GA Ferns, Medical Science Monitor 2002 8 1 11782689
5. Inflammatory cytokines and the risk to develop type 2 diabetes: Results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study. J Spranger A Kroke M Möhlig K Hoffmann MM Bergmann M Ristow H Boeing AFH Pfeiffer, Diabetes 2003 52 812 817 10.2337/diabetes.52.3.812 12606524
6. Inflammatory Markers and Risk of Developing Type 2 Diabetes in Women. FB Hu JB Meigs TY Li N Rifai JE Manson, Diabetes 2004 53 693 700 10.2337/diabetes.53.3.693 14988254
7. Correlation between cardiovascular disease and diabetes mellitus: Current concepts. RW Nesto, American Journal of Medicine 2004 8 116
8. Elevated C-reactive protein levels in overweight and obese adults. M Visser LM Bouter GM McQuillan MH Wener TB Harris, Journal of the American Medical Association 1999 282 2131 2135 10.1001/jama.282.22.2131 10591334
9. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. J Danesh JG Wheeler GM Hirschfield S Eda G Eiriksdottir A Rumley GD Lowe MB Pepys V Gudnason, N Engl J Med 2004 350 1387 1397 10.1056/NEJMoa032804 15070788
10. C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. DE Laaksonen L Niskanen K Nyyssönen K Punnonen TP Tuomainen VP Valkonen R Salonen JT Salonen, Diabetologia 2004 47 1402 1410 10.1007/s00125-004-1472-x (Pubitemid 39232426)
11. Interleukin-6 and the acute phase response. PC Heinrich JV Castell T Andus, Biochem J 1990 265 621 636 1689567
12. STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. D Zhang M Sun D Samols I Kushner, J Biol Chem 1996 271 9503 9509 10.1074/jbc.271.16.9503 8621622
13. Circulating markers of inflammation and atherosclerosis. L Lind, Atherosclerosis 2003 169 203 214 10.1016/S0021-9150(03)00012-1 12921971
14. Prostaglandins and leukotrienes: Advances in eicosanoid biology. CD Funk, Science 2001 294 1871 1875 10.1126/science.294.5548.1871 11729303
15. Prostaglandins as modulators of immunity. SG Harris J Padilla L Koumas D Ray RP Phipps, Trends Immunol 2002 23 144 150 10.1016/S1471-4906(01)02154-8 11864843
16. Development of multiple complications in type 2 diabetes is associated with the increase of multiple markers of chronic inflammation. JS Hwang TL Wu SC Chou C Ho PY Chang KC Tsao JY Huang CF Sun JT Wu, Journal of Clinical Laboratory Analysis 2008 22 6 13 10.1002/jcla.20207 18200579
17. Discrimination ratio analysis of inflammatory markers: implications for the study of inflammation in chronic disease. LM Browning JD Krebs SA Jebb, Metabolism 2004 53 899 903 10.1016/j.metabol.2004.01.013 15254884
18. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): A cohort study. MI Schmidt BB Duncan AR Sharrett G Lindberg PJ Savage S Offenbacher MI Azambuja RP Tracy G Heiss, Lancet 1999 353 1649 1652 10.1016/S0140-6736(99)01046-6 10335783
19. Elevated sialic acid, but not CRP, predicts features of the metabolic syndrome independently of BMI in women. LM Browning SA Jebb GD Mishra JH Cooke MA O'Connell MA Crook JD Krebs, International Journal of Obesity 2004 28 1004 1010 10.1038/sj.ijo.0802711 15211367
20. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. FE Silverstein G Faich JL Goldstein LS Simon T Pincus A Whelton R Makuch G Eisen NM Agrawal WF Stenson, et al. JAMA 2000 284 1247 1255 10.1001/jama.284.10.1247 10979111
21. Metabolic profiling of the response to an oral glucose tolerance test detects subtle metabolic changes. S Wopereis CM Rubingh MJ van Erk ER Verheij T van Vliet NH Cnubben AK Smilde J van der Greef B Van Ommen HF Hendriks, PLoS ONE 2009 4 4525 10.1371/journal.pone.0004525 19242536
22. NuGO contributions to GenePattern. PJ de Groot C Reiff C Mayer M Muller, Genes Nutr 2008 3 143 146 10.1007/s12263-008-0093-2 19034553
23. MAPPFinder: using Gene Ontology and GenMAPP to create a global gene-expression profile from microarray data. SW Doniger N Salomonis KD Dahlquist K Vranizan SC Lawlor BR Conklin, Genome Biol 2003 4 7 10.1186/gb-2003-4-1-r7 12540299
24. Large-scale human metabolomics studies: A strategy for data (pre-) processing and validation. S Bijlsma I Bobeldijk ER Verheij R Ramaker S Kochhar IA Macdonald B Van Ommen AK Smilde, Analytical Chemistry 2006 78 567 574 10.1021/ac051495j 16408941
25. Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. A Luria SM Weldon AK Kabcenell RH Ingraham D Matera H Jiang R Gill C Morisseau JW Newman BD Hammock, J Biol Chem 2007 282 2891 2898 10.1074/jbc.M608057200 17135253
26. Partial least squares for discrimination. M Barker W Rayens, Journal of Chemometrics 2003 17 166 173 10.1002/cem.785
27. H Martens T Naes, Multivariate Calibration Chichester, UK: John Wiley & Sons 1989
28. Renal vasodilator activity of 5,6-epoxyeicosatrienoic acid depends upon conversion by cyclooxygenase and release of prostaglandins. MA Carroll M Balazy P Margiotta JR Falck JC McGiff, Journal of Biological Chemistry 1993 268 12260 12266 8509363
29. Epoxyeicosatrienoic acids affect electrolyte transport in renal tubular epithelial cells: Dependence on cyclooxygenase and cell polarity. RM Nusing H Schweer I Fleming DC Zeldin M Wegmann, American Journal of Physiology - Renal Physiology 2007 293 1 10.1152/ajprenal.00171.2006 17494091
30. Differential effects of 5,6-EET on segmental pulmonary vasoactivity in the rabbit. AH Stephenson RS Sprague JL Losapio AJ Lonigro, American Journal of Physiology - Heart and Circulatory Physiology 2003 284 2153 61 12609822
31. Annexin 1: the new face of an old molecule. LH Lim S Pervaiz, FASEB J 2007 21 968 975 10.1096/fj.06-7464rev 17215481
32. Signal pathways involved in the regulation of prostaglandin E synthase-1 in human gingival fibroblasts. T Yucel-Lindberg T Olsson T Kawakami, Cell Signal 2006 18 2131 2142 10.1016/j.cellsig.2006.04.003 16766159
33. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-+|B activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Y Takada A Bhardwaj P Potdar BB Aggarwal, Oncogene 2004 23 9247 9258 15489888
34. Positive and negative regulation of NF-kB by COX-2. Roles of different prostaglandins. B Poligone AS Baldwin, Journal of Biological Chemistry 2001 276 38658 38664 10.1074/jbc.M106599200 11509575
35. Acute-phase proteins and other systemic responses to inflammation. C Gabay I Kushner, N Engl J Med 1999 340 448 454 10.1056/NEJM199902113400607 9971870